Tune in on Wednesday, September 27 at 7:00 p.m. EST for a not-to-be missed webinar from the Children’s Tumor Foundation (CTF) for an important announcement of the results of the INTUITT-NF2 platform clinical trial, and more. Extraordinary things are underway in the search for effective treatments for NF2-related schwannomatosis and all forms of schwannomatosis.
LEARN ABOUT:
– INTUITT’s innovative platform basket trial design, and the encouraging first results
– CTF’s game-chaning investment in the global SYNODOS “dream team” preclinical consortium
– SYNODOS’ groundbreaking screening process that identified promising treatments, including brigatinib
Innovative researchers, courageous patients, and bold investors have galvanized NF2-SWN research to a very pivotal moment. Be among the first to learn what is happening now, and how you can be a part of what is next on the NF2-SWN horizon.
The speakers for the panel include: Annette Bakker, PhD President, Children’s Tumor Foundation; Scott Plotkin, MD, PhD Massachusetts General Hospital; Brigid Garelik, MD, MPH Chief Medical Officer, Children’s Tumor Foundation.
All are invited to attend. Registration is free. Captioning will be available. To register, CLICK HERE.
